以體學為基礎的臨床試驗市場－全球產業規模、佔有率、趨勢、機會和預測：按階段、研究設計、適應症、地區和競爭格局分類，2021-2031年

全球基於體學的臨床試驗市場預計將從 2025 年的 272.3 億美元成長到 2031 年的 415.3 億美元，複合年成長率為 7.29%。

這些臨床試驗利用基因組學、蛋白質組學和代謝體學等高通量技術對患者進行分層並識別生物標記。關鍵的成長要素包括：為改善治療效果而向精準醫療的重大轉變、高通量定序成本的下降以及監管機構對生物標記主導藥物研發的鼓勵。儘管預計到2024年，個人化醫療將佔新核准療法的約38%，但該市場仍面臨著如何將複雜的多維數據無縫整合到標準化臨床工作流程中的挑戰。此外，對不同人群進行檢驗和分析所需的大規模基礎設施也阻礙了其更廣泛的擴充性。

市場促進因素

精準醫療和個人化醫療策略的快速發展是全球基於體學的臨床試驗市場的主要驅動力，它通過針對特定基因譜客製化療法並利用生物標記改進患者分層，從根本上改變了藥物研發，降低了臨床實驗失敗率。這一趨勢在腫瘤學領域尤其明顯，基因組分析已成為標準實踐，例如，美國食品藥物管理局 (FDA) 在 2024 年核准了 17 種新的抗癌藥物。同時，人工智慧 (AI) 與複雜的多組體學資料分析的融合，透過快速識別大量資料集中的細微關聯，消除了資料解讀的瓶頸，從而顯著加速了藥物發現進程。這種技術協同效應吸引了大量投資，例如，摩根大通預測英偉達 (NVIDIA) 醫療保健人工智慧部門到 2025 年的經常性收入將達到 10 億美元。這些因素共同推動了整個產業的成長和研發支出的增加，例如，Astra Zeneca預計 2024 年的研發支出將成長 24%。

市場挑戰

全球基於體學的臨床試驗市場成長的最大限制因素在於，將來自基因組學、蛋白質組學和代謝體學的大量多維生物數據整合到標準化的臨床工作流程中，其技術和操作上的複雜性。這需要大規模的基礎設施和先進的生物資訊能力，而許多臨床研究機構恰恰缺乏這些能力，造成瓶頸，導致研究週期延長和營運成本增加。這種摩擦限制了精準醫療計畫的擴充性，並提高了試驗的啟動和執行速度，尤其對於規模小規模的申辦者而言。到2024年，38%的臨床研究機構將舉措複雜性列為主要的營運挑戰。因此，不堪重負的研究機構面臨受試者招募延遲、數據品質風險增加、監管核准延遲等問題，並阻礙了體學主導的臨床策略的商業性化應用。

市場趨勢

當前市場趨勢包括單細胞定序和空間體學技術的廣泛應用。這些技術透過實現細胞異質性的高解析度分析，正在革新臨床試驗設計。它們能夠精確繪製腫瘤微環境和免疫反應的單細胞圖譜，並以前所未有的精確度識別抗藥性機制和預測性生物標記物，從而提升藥物研發中生物數據的精細化程度。這些技術的快速普及顯而易見，根據10x Genomics報告，到2025年1月，全球累計安裝的儀器數量將超過7,000台。同時，體學研究正從腫瘤學領域策略性地擴展到自體免疫疾病和罕見疾病領域，贊助公司擴大利用基因組和轉錄組數據對異質性患者群體進行分層，並開發針對單基因疾病的標靶RNA干擾療法。由於多組體學能力的提升，例如闡明不明確的疾病路徑和檢驗非惡性疾病中的新靶點，這種轉變正在為臨床研究創造新的、高盈利的前沿領域，Alnylam Pharmaceuticals 的產品總銷售額同比成長 103% 證明了這一點。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：利用體學進行臨床試驗的全球市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 階段（第一階段、第二階段、第三階段、第四階段）
  • 依研究類型分類的研究設計（擴大使用試驗、介入試驗、觀察性研究）
  • 適應症（循環系統、中樞神經系統疾病、遺傳性疾病、免疫系統疾病、腫瘤疾病、呼吸道疾病、皮膚疾病）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美體學臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲體學臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區組體學臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲體學臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲體學臨床試驗市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球基於體學的臨床試驗市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Parexel International Corporation
• Pharmaceutical Product Development（PPD）
• Charles River Laboratory
• ICON plc
• SGS SA
• Eli Lilly and Company
• Pfizer Inc.
• Covance Inc.
• Novo Nordisk
• Rebus Bio

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Omics-Based Clinical Trials Market is projected to grow from USD 27.23 Billion in 2025 to USD 41.53 Billion by 2031, at a 7.29% CAGR. These trials leverage high-throughput technologies like genomics, proteomics, and metabolomics for patient stratification and biomarker identification. Key growth drivers include the critical shift towards precision medicine for improved therapeutic outcomes, alongside decreasing high-throughput sequencing costs and regulatory encouragement for biomarker-driven drug development. While personalized medicines represented about 38 percent of newly approved therapeutics in 2024, the market faces challenges in seamlessly integrating complex multi-dimensional data into standardized clinical workflows, requiring substantial infrastructure for validation and analysis across diverse populations, thus hindering broader scalability.

Market Driver

The accelerated adoption of precision and personalized medicine strategies is a primary catalyst for the Global Omics-Based Clinical Trials Market, fundamentally transforming drug development by enabling treatments tailored to specific genetic profiles and improving patient stratification with biomarkers to reduce trial failure rates. This trend is particularly evident in oncology, where genomic profiling is standard, as demonstrated by the FDA's approval of 17 novel oncology drugs in 2024. Concurrently, the integration of artificial intelligence for complex multi-omics data analysis addresses data interpretation bottlenecks by rapidly identifying non-obvious correlations in vast datasets, significantly expediting discovery. This technological synergy attracts substantial investment, exemplified by J.P. Morgan's projection of NVIDIA's healthcare AI sector contributing $1 billion in recurring revenue by 2025, which collectively drives broader industry growth and increased R&D spending, such as AstraZeneca's 24 percent rise in 2024.

Market Challenge

The most significant impediment to the growth of the Global Omics-Based Clinical Trials Market is the technical and operational complexity of integrating high-volume multi-dimensional biological data from genomics, proteomics, and metabolomics into standardized clinical workflows. This necessitates substantial infrastructure and advanced bioinformatic capabilities, which many clinical research sites lack, creating bottlenecks that lead to prolonged study timelines and inflated operational costs. This friction limits the scalability of precision medicine initiatives, especially for smaller sponsors, and increases the failure rate of study initiation and execution, with 38 percent of clinical research sites identifying rising protocol complexity as a primary operational challenge in 2024. Consequently, research sites overwhelmed by data requirements experience slower patient recruitment and increased data quality risks, delaying regulatory approvals and dampening the commercial adoption of omics-driven clinical strategies.

Market Trends

Current market trends include the widespread adoption of single-cell sequencing and spatial omics technologies, which are revolutionizing clinical trial design by enabling high-resolution profiling of cellular heterogeneity. These tools precisely map the tumor microenvironment and immune responses at the individual cell level, enhancing the identification of resistance mechanisms and predictive biomarkers with unprecedented accuracy, thereby improving the granularity of biological data in drug development. The rapid uptake is evident, with 10x Genomics reporting its cumulative instrument base surpassed 7,000 units globally by January 2025. Simultaneously, omics research is strategically expanding beyond oncology into autoimmune and rare disease indications, where sponsors increasingly leverage genomic and transcriptomic data to stratify heterogeneous patient populations and develop targeted RNA interference therapies for monogenic disorders. This shift, driven by multi-omics' growing capability to elucidate obscure disease pathways and validate novel targets in non-malignant conditions, creates a lucrative new frontier for clinical investigation, underscored by Alnylam Pharmaceuticals' 103 percent year-over-year increase in total net product revenues.

Key Market Players

• Parexel International Corporation
• Pharmaceutical Product Development (PPD)
• Charles River Laboratory
• ICON plc
• SGS SA
• Eli Lilly and Company
• Pfizer Inc.
• Covance Inc.
• Novo Nordisk
• Rebus Bio

Report Scope

In this report, the Global Omics-Based Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Omics-Based Clinical Trials Market, By Phase

• Phase I
• Phase II
• Phase III
• Phase IV

Omics-Based Clinical Trials Market, By Study Design

• Expanded Access Studies
• Interventional Studies
• Observational Studies

Omics-Based Clinical Trials Market, By Indication

• Cardiology
• CNS Diseases
• Genetic Diseases
• Immunology
• Oncology
• Respiratory Diseases
• Skin Diseases

Omics-Based Clinical Trials Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Omics-Based Clinical Trials Market.

Available Customizations:

Global Omics-Based Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omics-Based Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Phase (Phase I, Phase II, Phase III, Phase IV)
  • 5.2.2. By Study Design (Expanded Access Studies, Interventional Studies, Observational Studies)
  • 5.2.3. By Indication (Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, Skin Diseases)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Omics-Based Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Phase
  • 6.2.2. By Study Design
  • 6.2.3. By Indication
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Omics-Based Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Phase
      • 6.3.1.2.2. By Study Design
      • 6.3.1.2.3. By Indication
  • 6.3.2. Canada Omics-Based Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Phase
      • 6.3.2.2.2. By Study Design
      • 6.3.2.2.3. By Indication
  • 6.3.3. Mexico Omics-Based Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Phase
      • 6.3.3.2.2. By Study Design
      • 6.3.3.2.3. By Indication

7. Europe Omics-Based Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Phase
  • 7.2.2. By Study Design
  • 7.2.3. By Indication
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Omics-Based Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Phase
      • 7.3.1.2.2. By Study Design
      • 7.3.1.2.3. By Indication
  • 7.3.2. France Omics-Based Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Phase
      • 7.3.2.2.2. By Study Design
      • 7.3.2.2.3. By Indication
  • 7.3.3. United Kingdom Omics-Based Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Phase
      • 7.3.3.2.2. By Study Design
      • 7.3.3.2.3. By Indication
  • 7.3.4. Italy Omics-Based Clinical Trials Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Phase
      • 7.3.4.2.2. By Study Design
      • 7.3.4.2.3. By Indication
  • 7.3.5. Spain Omics-Based Clinical Trials Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Phase
      • 7.3.5.2.2. By Study Design
      • 7.3.5.2.3. By Indication

8. Asia Pacific Omics-Based Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Phase
  • 8.2.2. By Study Design
  • 8.2.3. By Indication
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Omics-Based Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Phase
      • 8.3.1.2.2. By Study Design
      • 8.3.1.2.3. By Indication
  • 8.3.2. India Omics-Based Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Phase
      • 8.3.2.2.2. By Study Design
      • 8.3.2.2.3. By Indication
  • 8.3.3. Japan Omics-Based Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Phase
      • 8.3.3.2.2. By Study Design
      • 8.3.3.2.3. By Indication
  • 8.3.4. South Korea Omics-Based Clinical Trials Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Phase
      • 8.3.4.2.2. By Study Design
      • 8.3.4.2.3. By Indication
  • 8.3.5. Australia Omics-Based Clinical Trials Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Phase
      • 8.3.5.2.2. By Study Design
      • 8.3.5.2.3. By Indication

9. Middle East & Africa Omics-Based Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Phase
  • 9.2.2. By Study Design
  • 9.2.3. By Indication
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Omics-Based Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Phase
      • 9.3.1.2.2. By Study Design
      • 9.3.1.2.3. By Indication
  • 9.3.2. UAE Omics-Based Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Phase
      • 9.3.2.2.2. By Study Design
      • 9.3.2.2.3. By Indication
  • 9.3.3. South Africa Omics-Based Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Phase
      • 9.3.3.2.2. By Study Design
      • 9.3.3.2.3. By Indication

10. South America Omics-Based Clinical Trials Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Phase
  • 10.2.2. By Study Design
  • 10.2.3. By Indication
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Omics-Based Clinical Trials Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Phase
      • 10.3.1.2.2. By Study Design
      • 10.3.1.2.3. By Indication
  • 10.3.2. Colombia Omics-Based Clinical Trials Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Phase
      • 10.3.2.2.2. By Study Design
      • 10.3.2.2.3. By Indication
  • 10.3.3. Argentina Omics-Based Clinical Trials Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Phase
      • 10.3.3.2.2. By Study Design
      • 10.3.3.2.3. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Omics-Based Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Parexel International Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pharmaceutical Product Development (PPD)
• 15.3. Charles River Laboratory
• 15.4. ICON plc
• 15.5. SGS SA
• 15.6. Eli Lilly and Company
• 15.7. Pfizer Inc.
• 15.8. Covance Inc.
• 15.9. Novo Nordisk
• 15.10. Rebus Bio

16. Strategic Recommendations

17. About Us & Disclaimer